Repurposing Clinically Safe Drugs to Modulate DNA Repair in CRISPR Genome Editing

Study Background and Research Question

DNA double-strand breaks (DSBs) are critical lesions that can arise spontaneously or be induced by exogenous factors, including CRISPR-Cas9 genome editing. The cellular machinery employs several DSB repair pathways—primarily non-homologous end joining (NHEJ), microhomology-mediated end joining (MMEJ), and homology-directed repair (HDR)—each producing distinct mutational signatures. The ability to influence which repair pathway predominates at a DSB is central to improving the precision of genome editing for research, disease modeling, and therapeutic applications. However, pharmacological means to steer pathway choice remain underexplored, particularly using compounds with established safety profiles.

Key Innovation from the Reference Study

The referenced study (Macak et al., 2025) undertakes a high-throughput drug repurposing screen of over 7,000 FDA-approved compounds to systematically assess their impact on DSB repair pathway choice in human induced pluripotent stem cells (hiPSCs) undergoing CRISPR editing. By evaluating the mutational outcomes at Cas9-induced breaks, the researchers identify multiple drugs that selectively enhance or inhibit NHEJ, MMEJ, or HDR, thus providing a pharmacological toolkit for modulating genome editing outcomes. Additionally, the study reveals synergistic interactions and synthetic lethality opportunities relevant for precision medicine and cancer therapy.

Methods and Experimental Design Insights

The research employs a robust workflow in which hiPSCs expressing a doxycycline-inducible Cas9 (iCRISPR) system are subjected to genome editing at a defined locus (FRMD7) in the presence of test compounds. After editing, cell viability is assessed using a resazurin-based fluorescence assay, while DNA is extracted for next-generation sequencing to quantify editing outcomes. The mutational signatures are then assigned to known repair pathways, allowing the impact of each drug on NHEJ, MMEJ, and HDR to be rigorously quantified (reference).

• The drug library encompasses a broad spectrum of pharmacologically active molecules, ensuring relevance for repurposing in both research and clinical contexts.
• Sequencing data deconvolutes precise HDR events, small indels (NHEJ), and microhomology-dependent deletions (MMEJ), enabling pathway-specific analysis.
• Validation experiments investigate cellular factors such as ESR2 and AOX1, further linking drug effects to specific DNA repair proteins and offering mechanistic insights.

Core Findings and Why They Matter

The screening identifies a diverse set of clinically safe compounds capable of modulating DSB repair pathway choice. Notably, several drugs act as inhibitors or enhancers of NHEJ, MMEJ, and HDR, thus influencing the balance of imprecise versus precise genome editing outcomes. Among the key observations:

• Pathway modulation: Selective NHEJ inhibitors can shift repair toward HDR, enhancing the efficiency of precise genome edits. Conversely, MMEJ modulation alters the frequency and spectrum of predictable deletion events.
• Synergistic interactions: Silencing of ESR2 combined with NHEJ inhibition yields a 4.6-fold increase in HDR, illustrating the potential for combinatorial approaches to maximize precision (reference).
• Synthetic lethality: The study demonstrates that certain drugs can induce cell death only when a compensatory repair pathway is blocked, opening new avenues for targeted cancer therapies based on genetic vulnerabilities.

These findings are especially relevant for pancreatitis research compound development, calcium signaling modulation studies, and neurodegenerative disease model systems, where precise genome engineering is essential for modeling disease mechanisms and testing interventions.

Comparison with Existing Internal Articles

Several internal resources expand on the technical and translational implications of DSB repair pathway modulation:

• An in-depth guide on Dantrolene sodium salt details its ability to control ryanodine receptor-mediated calcium release, a process linked to DNA repair pathway activity and cellular stress responses.
• Another article discusses the application of ryanodine receptor antagonists in modulating calcium signaling for DNA repair research, providing protocol-level guidance for integrating these compounds in genome editing workflows.
• The broader implications for drug repurposing in genome editing are contextualized in this summary, which emphasizes the actionable strategies for enhancing editing precision and exploiting synthetic lethality in disease modeling.

These resources collectively support the notion that pharmacological modulation of intracellular signaling—such as calcium dynamics via ryanodine receptor antagonists—can reliably influence DNA repair outcomes, as demonstrated in the primary reference study.

Limitations and Transferability

While the study provides a comprehensive resource for drug-induced modulation of DNA repair pathways, several limitations warrant consideration:

• Screening was conducted in a single hiPSC line and at a single genomic locus, which may limit generalizability across cell types and target sites.
• One replicate per condition reduces statistical power for low-frequency effects, though the high throughput and depth of sequencing mitigate this issue for predominant outcomes.
• Translation of findings to in vivo or clinical settings will require additional pharmacokinetic and toxicity studies, despite the use of clinically approved compounds.

Nevertheless, the methodology is adaptable to a range of cell systems and genome editing platforms, and the identification of pathway-selective modulators provides a foundation for broader application in disease modeling and therapeutic engineering.

Protocol Parameters

• Drug treatment timing: Apply candidate pathway modulators during the genome editing window (e.g., 1–24 hours post-transfection) to maximize repair pathway influence, as performed in the reference study.
• Editing system: Use inducible Cas9 systems to synchronize editing events and facilitate precise assessment of repair outcomes.
• Sequencing and analysis: Employ targeted amplicon sequencing to distinguish HDR, NHEJ, and MMEJ signatures at the edited locus.
• Validation: Where possible, verify drug effects in multiple cell lines and at additional genomic targets to ensure reproducibility.

Why this cross-domain matters, maturity, and limitations

The intersection of genome editing, DNA repair modulation, and drug repurposing has immediate implications for both basic and translational research. Pharmacological control of repair pathway choice enhances the fidelity of disease models—such as those for neurodegeneration, ischemia, and pancreatitis—and enables more reliable testing of therapeutic strategies. However, while preclinical evidence is robust, translation to clinical application must account for differences in cell context, drug metabolism, and possible off-target effects. Thus, while pathway modulators like ryanodine receptor antagonists show promise in vitro, further validation in disease-relevant systems is essential.

Research Support Resources

Researchers seeking to investigate intracellular calcium signaling and its impact on DNA repair pathway choice can utilize Dantrolene, sodium salt (SKU B6329), a high-purity ryanodine receptor antagonist with well-characterized pharmacology and utility in calcium signaling modulation and ischemia and hypoxia research. The compound’s calmodulin-dependent inhibition profile and rigorous quality control make it a suitable tool for experimental workflows aligned with those described in the reference study. For further methodological detail and troubleshooting, internal resources such as the guides on Dantrolene sodium salt provide actionable protocols and practical tips to optimize experimental design.